Radiosensitivity Differences Between Liver Metastases Based on Primary Histology Suggest Implications for Clinical Outcomes After Stereotactic Body Radiation Therapy
Kamran A. Ahmed, Jimmy J. Caudell, Ghassan E. El-Haddad et al. · International Journal of Radiation Oncology*Biology*Physics · 2016
Cited by 161 works. doi:10.1016/j.ijrobp.2016.03.050
Authors
- Kamran A. Ahmed
- Jimmy J. Caudell
- Ghassan E. El-Haddad
- Anders Berglund
- Eric A. Welsh
- Binglin Yue
- Sarah E. Hoffe
- A.O. Naghavi
- Yazan Asad Abuodeh
- Jessica M. Frakes
- Steven A. Eschrich
- Javier F. Torres–Roca
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- The Collinearity Problem in Linear Regression. The Partial Least Squares (PLS) Approach to Generalized Inverses
- Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung Metastases
- Stereotactic Single-Dose Radiation Therapy of Liver Tumors: Results of a Phase I/II Trial
- Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver Metastases
- Phase II study on stereotactic body radiotherapy of colorectal metastases
- Oligometastases Treated With Stereotactic Body Radiotherapy: Long-Term Follow-Up of Prospective Study
- Phase I Study of Individualized Stereotactic Body Radiotherapy of Liver Metastases
- A prospective pilot study of curative‐intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions
- Stereotactic radiotherapy of primary liver cancer and hepatic metastases